News | January 03, 2024
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes